Statins are prescribed based on a cardiovascular risk calculation at a specific point in time. That risk changes. Weight changes, lifestyle changes, age changes the calculation. Whether the original decision still holds deserves a proper clinical answer.
Full page coming soonThe clinical case for statins is strongest in secondary prevention. In primary prevention, the risk-benefit calculation is more nuanced and more personal.
Myalgia, myopathy, and rhabdomyolysis: the spectrum of muscle side effects, how common they actually are, and what the options are.
Atorvastatin vs rosuvastatin vs pravastatin: different potency, different side effect profiles. Sometimes switching resolves symptoms without stopping.
LDL, non-HDL, ApoB, and what each actually tells you about cardiovascular risk. What to ask for at your next blood test.
The clinical conditions in which statin deprescribing is genuinely warranted: frailty, limited life expectancy, primary prevention with low absolute risk.
The evidence for coenzyme Q10 in statin-associated myopathy, what it shows and what it doesn't.
In the meantime, if you have questions before this page is complete, contact the practice directly, or book a consultation online. Every enquiry is reviewed personally by Dr Dan Reardon.